Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...
CAR T-cell therapy on the National Health Service offers adults with fast-moving B-cell leukemia years of life, fewer side ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
MedPage Today on MSN
CAR7 gene therapy shows promise in T-cell ALL
One patient still in remission 3 years after single infusion of base-edited CAR7 T cells ...
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...
Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...
WPBF Channel 25 on MSN
'They don't yet know each other': Surprises expected at Gift of Life 5K run in Boca Raton
The Gift of Life Marrow Registry's 15th annual Steps for Life 5K in South Florida will feature a heartwarming introduction ...
CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.
Cipla partners with ImmunoACT to commercialise CAR-T cell therapy in South Africa, Algeria, and Morocco. Expanding access to innovative cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results